Figure 4.
Oseltamivir treatment impaired the fungal killing capacity of mouse splenocytes and human PBMCs
(A) Killing capacity of splenocytes from immunocompetent C57BL/6J mice treated with (red bars) or without (black bars) oseltamivir and infected with A. fumigatus (1 × 106/mL) (empty bars) or left uninfected (striped bars).
(B and C) PBMCs and neutrophils were stimulated with A. fumigatus conidia (MOI of 4:1) in the presence or absence of oseltamivir carboxylate (n = 16). A killing assay was performed after 4 h of incubation at 37°C. Cells were lysed with H2O and plated on Sabouraud dextrose agar (SDA) in serial dilutions, and the remaining CFUs were counted after 24-h incubation at 37°C.
(D and E) ROS production from immune cells in lung homogenates of immunocompetent mice treated with or without oseltamivir and infected with A. fumigatus or left uninfected.
(F and G) ROS induction from PBMCs and neutrophils stimulated with A. fumigatus conidia in the presence or absence of oseltamivir carboxylate (n = 11).
Data are shown as mean ± SEM. ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05.